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Treatment of Ruptured Intracranial Aneurysms Using the Woven 
EndoBridge Device: A Two-Center Experience 
 
Abstract 
 
Background: The Woven EndoBridge (WEB) device is a new treatment modality developed 
for broad-necked unruptured intracranial aneurysms (IA) but shows potential for the 
treatment of ruptured IAs as well. Our aim was to describe 6-month aneurysm obliteration 
rates, clinical outcomes and procedure related complications after WEB treatment for 
ruptured IAs from two academic centers.  
 
Methods: We conducted a retrospective observational study, including all consecutive 
patients treated with the WEB device (WEB Single Layer [SL] and Single-Layer Sphere [SLS]) 
for a ruptured IA causing acute subarachnoid hemorrhage (SAH) between 2014 (start of use) 
and 2017. Primary outcome was angiographic aneurysm obliteration (Beaujon Occlusion 
Scale Score [BOSS]) rate. Secondary outcomes were early re-bleedings, complications and 
patient outcome (death and modified Rankin Scale).  
 
Results: A total of 33 patients with ruptured IAs were treated 0-4 days from IA rupture. Out 
of 27 survivors, six-month angiographic follow-up was available for 26 patients, out of which 
81% showed complete occlusion. Of the 27 survivors, 24 patients (89%) had a favorable 
neurological outcome at six-months after SAH. Two aneurysms were re-treated (8% of all). 
There was one fatal procedure related complication. No early aneurysm re-bleedings were 
noted.  
 
Conclusion: For anatomically suitable ruptured IAs, WEB device treatment seems to be safe 
and results in acceptable occlusion rates. Still, larger studies with long-term results are 
needed before recommendations can be made.  
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Introduction 
In the past decade, following the International Subarachnoid Aneurysm Trial, there has been 
a trend towards endovascular treatment of ruptured intracranial aneurysms (IA).
1–4
 The 
mainstay endovascular treatment of ruptured IAs is coiling. Still, there has been concerns 
regarding long-term results of ruptured IAs treated with coiling.
5–7
 Other techniques used for 
unruptured IAs, such as sent-assisted coiling and the use of flow diverters are associated 
with higher obliteration rates but their use in ruptured IAs are limited due the risk of 
thromboembolic and hemorrhagic complications.
8–11
 
 
In 2010, the WEB™ device (Sequent Medical, Aliso Viejo, California, USA), an intrasaccular 
flow diversion device was introduced into the European market.
12,13
 Since its introduction, 
numerous studies have shown very high obliteration rates for unruptured IAs.
14–18
 A major 
benefit of the WEB device is that it does not require dual antiplatelet therapy. Thus, lately 
the WEB device has also been used for ruptured IAs in the acute phase of subarachnoid 
hemorrhage (SAH). Although, there is extensive evidence supporting the use of WEB device 
in unruptured IAs, only few studies have looked at ruptured IAs.
19–23
  
 
The primary aim of this study was to assess aneurysm obliteration rates following 
endovascular treatment using the WEB device for ruptured IAs. We hypothesized that 
occlusion rates of WEB treated ruptured IAs would be similar to previous reports of coiled 
ruptured IAs. Secondary aims was to assess frequency of early aneurysm re-bleedings, 
procedure related complications and patient neurological outcome.  
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Methodology 
We obtained local research approvals  from the two hospitals and the need for informed 
consent was waived by respective research committee due to the retrospective nature of 
the study (HUS/125/2017 and T011/014/18).  
 
We conducted an open-cohort retrospective study, including all consecutive patients treated 
endovascularly with the WEB device for a ruptured intracranial aneurysm at two University 
hospitals in Finland (Helsinki University Hospital [HUS], Turku University Hospital [TYKS]) 
from November 2014 (start of use) until December 2017. All patients were treated in the 
acute SAH stage. The decision to use the WEB device was made by a multidisciplinary team 
consisting of neurovascular neurosurgeons and neurointerventionalists. The indications for 
using the WEB device are wide-necked bifurcation aneurysms, although it was occasionally 
used in “atypical locations” (Fig. 1).
24
 
 
The WEB™ embolization system and endovascular procedure 
The WEB device is an intrasaccular device consisting of braided nitinol wire forming a sphere 
(WEB SLS) or a more barrel shaped form (WEB SL). The WEB embolization system is well 
suited for treating broad-neck saccular aneurysms.
12,13
  
 
All procedures were performed by experienced neurointerventionalists. No antiplatelet 
treatment was routinely started prior to treatment. All procedures were conducted under 
heparinization. An 8F/6F combination of guiding catheters or a 6F catheter alone was used. 
An appropriately sized VIA catheter (Sequent Medical, Aliso Viejo, California, USA) was 
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placed at the fundus of the aneurysm from which the WEB device was deployed. The type 
(WEB SL or SLS) and size of the WEB was decided based upon measurements from 3D 
rotational angiographic and orthogonal 2D projection measurements. In case of suboptimal 
fitting, the WEB size was changed. Acetylsalicylic acid (Aspirin) was not routinely used.  
 
Extracted variables 
We obtained all patient data through electronic health care records (EHRs) and by reviewing 
radiological images from the hospitals’ Picture Achieving Communication Systems (PACS). 
We obtained information regarding pre-SAH modified Rankin Scale (mRS, see below) history 
of hypertension and smoking status through EHRs. We obtained the following SAH-related 
admission characteristics: Glasgow Coma Scale score (GCS), Hunt & Hess Classification of 
SAH, pupillary light reactivity, modified Fischer scale, external ventricular drain (EVD), days 
from SAH to hospital admission and days from SAH to WEB treatment. We considered a 
Hunt & Hess class of 4–5 as poor grade SAH.  
 
Follow-up 
We perform routine angiographic follow-up at 6-months after treatment (with small 
variations depending on the patient’s clinical condition). During SAH treatment, we obtain a 
routine head computerized tomography (CT) on the first post-procedural day. We obtain 
follow-up head CTs according to clinical indications. Long-term clinical follow-up is 
conducted through the neurosurgical or neurological outpatient clinics.      
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Outcomes 
As the primary outcome of interest we used radiological aneurysm occlusion. Two 
neuroradiologists evaluated treatment results according to the Beaujon Occlusion Scale 
Score (BOSS, 0: no residual flow in the aneurysm/WEB; 0´: opacification of the proximal 
recess of the WEB; 1: residual flow inside the WEB; 2, neck remnant; 3: aneurysm remnant) 
from the control digital subtraction angiography conducted closest to 6-months after 
SAH.
25,26
 We considered BOSS 0 and 0´as complete occlusion of the aneurysm.
14,18
  As 
secondary outcome of interests we looked at aneurysm re-bleeding, and WEB treatment 
related thromboembolic complications based upon follow-up head CT imaging. We also 
report death rates and neurological outcomes, according to the modified Rankin Scale (a 
mRS of 0 [no symptoms at all] to 2 [slight disability] were considered favorable neurological 
outcome).
27,28
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Results 
Of totally 331 endovascularly treated aneurysman SAH patients treated, a total of 33 
patients (HUS, N=12 treated with WEB out of 166 endovascularly treated SAH patients; TYKS, 
N=21 treated with WEB out of 165 endovascularly treated SAH patients) were treated 
between November 2014 and December 2017. Only in one patient a help device (stent) was 
used and was administered dual antiplatelet therapy (stent used due to protrusion of WEB 
into parent artery). Three patients with broad based aneurysms were administered 
acetylsalicylic acid for two to six weeks.  All except one patient was admitted to the hospital 
on the same day of SAH (one patient the next day). Two thirds or patients were treated on 
the IA rupture day and one third were treated on days 1 to 3. All patients had a pre-SAH mRS 
of 0. Patient characteristics are shown in Table 1. Median age was 56 years (IQR 49–67), no 
patients had previously suffered from SAH, 50% of patients were smokers and 44% had a 
diagnosis of arterial hypertension. Twenty-one percent had poor grade SAH, median 
modified Fischer scale was 4 (IQR 3–4) and 18% of patients had intracerebral hemorrhage. 
Median time from SAH to WEB treatment was on 0 (IQR 0–1). Sixty-one percent of all 
treated aneurysms were located in the anterior circulation. Basilar artery and anterior 
communicating artery aneurysm were the most common locations. Median aneurysm size 
was 7 mm. 
 
Primary Outcome: Aneurysm Occlusion Rate 
Of 33 patients, 6 patients died and were not subject to follow-up angiography. Out of 27 
survivors, follow-up angiography was available for 26 patients. Median time to angiographic 
follow-up was 193 days (IQR 179-220). Of these 21 of 26 patients (81%) showed complete 
occlusion of the treated aneurysm. Five of 26 patients (19//23%) showed incomplete 
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occlusion (four neck remnants [Fig. 2], one aneurysm remnant). Of these incomplete 
occluded aneurysms, two were anterior communicating artery aneurysms, two were basilar 
artery aneurysms and one was a middle cerebral artery bifurcation aneurysm. Of these 
incompletely occluded aneurysms, two were re-treated (8% of all; one anterior 
communicating aneurysm and one middle cerebral artery bifurcation aneurysm). Both 
patients undergoing re-treatment had an mRS of 0 and 1 before and after the re-treatment.  
 
Secondary Outcomes: Patient Outcome, Complications and Early Re-Bleedings 
Six patients (18%) died following SAH (4 to 44 days following SAH). These non-survivors were 
significantly older than survivors (median age for non-survivors 70 years [IQR 58-78] versus 
median age for survivors 52 years [IQR 47-65], p=0.011). Sixty-seven percent of non-
survivors had a poor grade SAH compared to 11% for survivors (p=0.003). Two patients died 
due to severe delayed cerebral ischemia. One patients experienced re-bleeding in the angio 
suite prior to treatment. One patient suffered from a massive pulmonary embolism nine 
days after treatment and was administered intravenous thrombolysis and subsequently 
developed a fatal massive intracerebral hemorrhage at a distant site from the treated 
aneurysm (anterior communicating artery) and was, thus, not classified as an early re-bleed 
(Fig. 3). One elderly poor grade SAH patient suffered out of hospital cardiac arrest in 
conjunction with aneurysm rupture and died after nine days of treatment. One good grade 
SAH patient did not wake up after endovascular treatment and died after three weeks of 
treatment (ruptured left sided pericallosal aneurysm). Autopsy report showed hydrophilic 
polymeric embolisation of the left hemisphere and this was the only directly treatment 
related complication. Further, three patients (9%) suffered from clinically silent brain 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
ischemic lesions related to the WEB treatment (all of these patients had a favorable 
neurological outcome). 
 
No patient experienced post-WEB treatment re-bleeding (Table 2). Seven patients (21%) 
experienced SAH related delayed cerebral ischemia (out of which 3 patients died, 2 had an 
unfavorable neurological outcome and 2 a favorable neurological outcome).  
 
Median time to neurological outcome assessment was 198 days (IQR 177-235). Of 27 
survivors, 24 patients (89%) had a favorable neurological outcome (mRS 0-2) and 3 patients 
(11%) an unfavorable neurological outcome (mRS 3-5). Including all patients, the rate of 
favorable neurological outcome was 73% (N=24/33) and the rate of unfavorable neurological 
outcome 27% (N=9/33).  
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Discussion 
Key findings 
In this two-center retrospective study, we showed that complete angiographic occlusion rate 
for WEB device treated ruptured IAs to be 81%. Two aneurysms (8%) required re-treatment. 
No early re-bleedings were noted but there was one fatal procedure related complication. 
Of patients surviving the acute phase of SAH, the rate of favorable neurological outcome 
was 89%.  
 
Comparison with previous studies 
There are some previous studies investigating the use of the WEB device for the treatment 
of ruptured IAs. In 2014, Caroff and colleagues reported their case-series of six ruptured IAs 
being treated with the WEB device and found an adequate occlusion rate of 67% at 3-
months (complete occlusion, small neck remnant, or opacification of the first chamber).
19
  
Van Rooij WJ and colleagues showed in their 18 angiographically followed up patients a 
complete occlusion rate of 83%.
20
 Liebig and colleagues found a complete occlusion rate of 
60% (15 out of 25 patients) at 4-months and a complete occlusion rate of 56% (5 out of 9 
patients) at 13-months.
22
 Popielski and colleagues found a complete occlusion rate of 59% at 
3-months (13 out of 22 patients) and 58% at 12-months (7 out of 12 patients).
21
 In the 
largest clinical series on WEB treated ruptured IAs, Van Rooij SBT and colleagues showed a 
complete occlusion rate of 73% (54 out of 74 patients).
23
 Thus, the complete occlusion rate, 
of WEB treated ruptured IAs, seems to vary between 56% and 83%. Our results fare well 
with these, with an overall complete occlusion rate of 81%.  
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It should be mentioned that the BOSS scale for the angiographic evaluation of WEB device 
treated results is rather strict. As most previous studies, we only considered no flow inside 
the aneurysm or the WEB and opacification of the proximal recess as complete occlusions.
26
 
Still, it is possible that a slight level of flow inside the WEB (BOSS 1) and a small aneurysm 
neck remnant (BOSS 2) could be acceptable radiological outcomes. Especially in elderly 
patients, where the main goal of treatment is prevention of early re-bleedings with less 
focus on long-term follow-ups. If we would have classified small neck remnants as adequate 
occlusion, our adequate occlusion rate would have been 96% (25 out of 26). Yet, before 
long-term studies verify the stability of BOSS grades 1 and 2, we do not think it adequate to 
accept suboptimal occlusions especially as complication rates after re-treatment is low.
29,30
  
 
The golden standard for endovascular treatment of ruptured IAs remains to be standard 
coiling (with or without balloon-remodeling), avoiding implants that require antiplatelet 
therapy in the acute setting of SAH. In a large retrospective series including ruptured IAs, 
complete occlusion rate at 3-12 months after coiling was 45% and 38%  at 12-months.
7
 In 
the ISAT study, 66% of endovascularly coiled ruptured IAs were completely occluded at 2 to 
12 months.
31
 Thus, angiographic results of WEB device treated ruptured IAs seems to at least 
match those of coiled ones. Still, one has to remember that all studies on using the WEB 
device for ruptured IAs, including our study, are rather small observational studies with a 
selected set of patients with anatomically suitable aneurysms for WEB treatment and, thus, 
the results cannot be directly compared, especially as the WEB is mainly used for broad 
based aneurysms, which is associated with a higher recurrence rate.
7
 Furthermore, the WEB 
device is used for the treatment of aneurysms maximally 10 mm large (max WEB size 11 x 9 
mm), while coil embolization does not per se have any upper size limit. Consequently, since 
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aneurysm size is one of the major risk factors for aneurysm recurrence it biases the results 
towards better occlusion rates for WEB device treated aneurysms when compared to 
unselected series of coil embolized aneurysms.
7
  Thus, randomized studies or case-matched 
series comparing WEB device treatment to coil embolization are needed as are long-term 
follow-up studies after WEB device treatment.   
 
The rate of complications was low. Three patients suffered from clinically silent ischemic 
lesions and one patient had an unexpected extremely rate and severe complication, 
resulting in hydrophilic polymeric embolisation of the left hemisphere, which has been 
described elsewhere.
32
 Iatrogenic polymeric embolisation  has been associated with a wide 
range of percutaneous intravascular diagnostics and therapeutic interventions and the fact 
that it happened in this small series is hardly related to the WEB device itself.
33,34
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Conclusions 
In this selected patient cohort of anatomically suitable ruptured IAs, WEB device treatment 
seems to be safe and results in acceptable occlusion rates. Still, larger studies with long-term 
results are needed before recommendations can be made. 
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Figure legends 
 
Figure 1: Showing the configuration of typical aneurysms treated with the WEB device (prior 
to treatment to the left and after WEB device deployment to the right). In the upper part an 
anterior communicating artery aneurysm and in the middle part a basilar tip artery 
aneurysm and in the lower part a posterior inferior cerebellar artery aneurysm, the first two 
locations being “typical locations” and the last one being an “atypical location”.  
 
Figure 2: Showing incomplete occlusion of an anterior communicating artery aneurysm 
(upper row)  and a basilar tip artery aneurysm (lower row). To the left the pre-WEB device 
images, in the middle the immediate post-WEB deployment images and to the right the 6-
month control showing aneurysm neck remnant.  
 
Figure 3: To the left the 1-day post-WEB treatment CT image and to the right the CT image 
following thrombolysis therapy for a massive pulmonary embolism nine days after 
treatment.  
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Table 1: Patient baseline characteristics  
 All (N=33) HUS (N=12) TYKS (N=21) 
Age, median (IQR) 56 (49-67) 51 (47–58) 60 (52-72) 
Previous SAH 0 0 0 
Hypertension 14 (44%) 4 (33%) 10 (50%) 
Smoking*    
   No 10 (42%) 6 (50%) 4 (33%) 
   Current 12 (50%) 5 (42%) 7 (58%) 
   Ex-smoker 2 (8%) 1 (8%) 1 (8%) 
Admission GCS score  14 (10-15) 14 (5–15) 14 (10-15) 
Pupillary light reactivity    
   Both react 32 (97%) 12 (100%) 20 (95%) 
   One react 1 (3%) 0 1 (5%) 
   None react 0 0 0 
Admission motor scale,  median (IQR) 6 (5-6) 6 (2–6) 6 (5-6) 
Hunt & Hess, median (IQR) 2 (2-3) 3 (2–5) 2 (1-3) 
   1–3 26 (79%) 9 (75%) 17 (81%) 
   4–5 7 (21%) 3 (25%) 4 (19%) 
Modified Fisher scale, median (IQR) 4 (3-4) 4 (4–4) 3 (3-4) 
ICH 6 (18%) 2 (17%) 4 (19%) 
External ventricular drain    
   Before treatment 8 (24%) 3 (25%) 5 (24%) 
   After treatment 12 (36%) 4 (33%) 8 (38%) 
   Not at all 13 (40%) 5 (42%)  
Time from SAH to WEB (d), median (IQR)  0 (0–1) 0 (0–1) 0 (0–1) 
Length of ICU stay (d), median (IQR) 10 (6–15) 9 (5–15) 10 (6–16) 
Length of hospital stay (d), median (IQR) 15 (12–19) 16 (14–20) 15 (10–18) 
Aneurysm location    
   ICA 3 (9%) 1 (8%) 2 (10%) 
   ACoA 9 (28%) 6 (50%) 3 (14%) 
   MCA bifurcation 7 (21%) 0 (0%) 7 (33%) 
   Pericallosal 1 (3%) 0 (0%) 1 (5%) 
   Basilar 12 (36%) 4 (34%) 8 (38%) 
   PICA 1 (3%) 1 (8%) 0 (0%) 
Aneurysm size (mm), median (IQR)    
   Length 7 (5–10) 7 (5–10) 7 (6–10) 
   Width 6 (5–8) 5 (4–8) 7 (6–8) 
   Depth 7 (5–9) 6 (3–8) 7 (6–10) 
Continuous variables shown as medians with interquartile ranges. Categorical variables shown as 
numbers and percentages. 
*Data missing for 9 patients. 
Abbreviations: IQR, Interquartile Range; GCS, Glasgow Coma Scale; ICH, Intracranial Hemorrhage; SAH, 
Subarachnoid Hemorrhage; WEB, Woven EndoBridge Device; ICU, Intensive Care Unit; ICA, Internal 
Carotid Artery; ACoA, Anterior Communicating Artery; MCA, Middle Cerebral Artery; PICA, Posterior 
Inferior Cerebellar Artery. 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 2: Primary and secondary outcomes 
 All patients (N=33) 
Aneurysm occlusion (BOSS)*  
Complete occlusion 21/26 (81%) 
   No residual flow in the aneurysm/WEB 12/26 (46%) 
   Opacification of the proximal recess of the WEB 9/26 (35%) 
Incomplete occlusion 5/26 (19%) 
   Residual flow inside the WEB 0 (0%) 
   Neck remnant 4 (15%) 
   Aneurysm remnant 1 (4%) 
Neurological outcome (mRS)  
   Favorable neurological outcome 24/33 (73%) 
   Unfavorable neurological outcome 9/33 (27%) 
Deaths 6/33 (18%) 
Early aneurysm re-bleedings 0/33 (0%) 
Procedure-related ischemia  
   Silent infarcts 3/33 (9%) 
   Lethal infarct 1/33 (3%) 
*For 26 patients with available angiographic follow-up. 
 
Values shown as patients divided with total amount of patients (percentages). 
 
Complete occlusion is defined as BOSS 0 (no residual flow in the aneurysm) and 
0´(opacification of the proximal recess).  
 
Favorable neurological outcome is defined as a modified Rankin Scale of 0 (no symptoms) to 2 
(slight disability). 
 
Abbreviations: BOSS, Beaujon Occlusion Scale Score; mRS, modified Rankin Scale. 
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Abbreviations 
 
 
BOSS, Beaujon Occlusion Scale Score  
 
CT, Computerized Tomography 
 
EHR, Electronic Health Care Record 
 
EVD, External Ventricular Drain 
 
GCS, Glasgow Coma Scale 
 
HUS, Helsinki University Hospital 
 
IA, Intracranial Aneurysm 
 
IQR, Interquartile Range 
 
mRS, modified Rankin Scale 
 
PACS, Picture Achieving Communication Systems 
 
SAH, Subarachnoid Hemorrhage 
 
SL, Single Layer 
 
SLS, Single Layer Sphere 
 
TYKS, Turku University Hospital 
 
WEB, Woven Endobridge Device 
 
